{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:25:35Z","timestamp":1786951535302,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD098977"],"award-info":[{"award-number":["R01HD098977"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01AI134367"],"award-info":[{"award-number":["2R01AI134367"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI124414"],"award-info":[{"award-number":["P30 AI124414"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068613"],"award-info":[{"award-number":["UM1 AI068613"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR004400"],"award-info":[{"award-number":["UM1 TR004400"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small studies have documented variable neutralizing activity of cervicovaginal lavage (CVL) against herpes simplex viruses (HSVs). This neutralizing activity is lower in women with bacterial vaginosis, a syndrome associated with HSV recurrences. However, the mechanisms have not been fully defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We took advantage of a biobank of CVL and linked data including HSV neutralizing activity measured by plaque reduction assay, Nugent scores, and concentrations of CVL immune mediators. We fractionated CVL to enrich or deplete candidates and quantified neutralizing activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CVL reduced viral plaque formation by 40.82% \u00b1 37.59% (mean \u00b1 SD, n = 361). Activity was independent of HSV serostatus, significantly lower in those with a Nugent score of 7 to 10 (n = 176, P &amp;lt; .05), and positively correlated with CVL concentrations of IgG (P = .001, n = 87) and human neutrophil peptides 1 to 3 (P &amp;lt; .001, n = 119). Activity was enriched in the immunoglobulin fraction but reduced when IgG, but not IgA, was depleted. Increasing concentrations of an anti\u2013glycoprotein E monoclonal antibody overcame the neutralizing activity, suggesting that interactions between IgG Fc and glycoprotein E (gE), a viral Fc gamma receptor, contribute. Moreover, CVL had less HSV inhibitory activity against a gE-null virus. Treatment of CVL with peptide-N-glycosidase F, which cleaves IgG N-glycans, reduced HSV neutralizing activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Interactions between IgG Fc and viral gE, independent of Fab specificity, contribute to cervicovaginal antiviral activity. Antiviral activity is reduced with dysbiosis, presumably reflecting lower IgG levels and differences in N-glycans that lead to decreased gE interactions. Results highlight the importance of developing and implementing strategies to protect against vaginal dysbiosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag398","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:20:33Z","timestamp":1785324033000},"source":"Crossref","is-referenced-by-count":0,"title":["Mucosal IgG Interacts With Herpes Simplex Virus Glycoprotein E, an Fc\u03b3 Receptor Mimetic, and Neutralizes Viral Infection: Activity Is Reduced in the Setting of Vaginal Dysbiosis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0530-122X","authenticated-orcid":false,"given":"Aakash","family":"Mahant Mahant","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2701-1115","authenticated-orcid":false,"given":"Matthew","family":"Gromisch","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-1385","authenticated-orcid":false,"given":"Richard","family":"Hunte","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-354X","authenticated-orcid":false,"given":"Jennifer T","family":"Aguilan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-333X","authenticated-orcid":false,"given":"Kerry","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]},{"name":"Department of Medicine, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla J","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-0786","authenticated-orcid":false,"given":"Betsy C","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Albert Einstein College of Medicine , Bronx , New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026081702563628500_jiag398-B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clp.2021.03.003","article-title":"Neonatal herpes simplex virus disease: updates and continued challenges","volume":"48","author":"Samies","year":"2021","journal-title":"Clin Perinatol"},{"key":"2026081702563628500_jiag398-B2","doi-asserted-by":"crossref","first-page":"e164317","DOI":"10.1172\/JCI164317","article-title":"HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal","volume":"133","author":"Pierce","year":"2023","journal-title":"J Clin Invest"},{"key":"2026081702563628500_jiag398-B3","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"key":"2026081702563628500_jiag398-B4","doi-asserted-by":"crossref","first-page":"e2230","DOI":"10.1371\/journal.pone.0002230","article-title":"Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa","volume":"3","author":"Abu-Raddad","year":"2008","journal-title":"PLoS One"},{"key":"2026081702563628500_jiag398-B5","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"2026081702563628500_jiag398-B6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1056\/NEJMe068302","article-title":"Synergistic copathogens\u2014HIV-1 and HSV-2","volume":"356","author":"Corey","year":"2007","journal-title":"N Engl J Med"},{"key":"2026081702563628500_jiag398-B7","doi-asserted-by":"crossref","first-page":"e001875","DOI":"10.1136\/bmjgh-2019-001875","article-title":"The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study","volume":"5","author":"Looker","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2026081702563628500_jiag398-B8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/OLQ.0b013e31816fcaf8","article-title":"Risk factors for incident herpes simplex type 2 virus infection among women attending a sexually transmitted disease clinic","volume":"35","author":"Gallo","year":"2008","journal-title":"Sex Transm Dis"},{"key":"2026081702563628500_jiag398-B9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/infdis\/jiaf444","article-title":"Cervicovaginal secretions in young women with bacterial vaginosis enhance HIV infection","volume":"232","author":"Keller","year":"2025","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/QAI.0b013e31826867ae","article-title":"Changes in the soluble mucosal immune environment during genital herpes outbreaks","volume":"61","author":"Keller","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081702563628500_jiag398-B11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-0897.2009.00768.x","article-title":"Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception","volume":"63","author":"Shust","year":"2010","journal-title":"Am J Reprod Immunol"},{"key":"2026081702563628500_jiag398-B12","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1086\/497168","article-title":"Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection","volume":"192","author":"John","year":"2005","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiz203","article-title":"Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome","volume":"220","author":"Keller","year":"2019","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B14","doi-asserted-by":"crossref","first-page":"e13845","DOI":"10.1111\/aji.13845","article-title":"Genetic predictors for bacterial vaginosis in women living with and at risk for HIV infection","volume":"91","author":"Murphy","year":"2024","journal-title":"Am J Reprod Immunol"},{"key":"2026081702563628500_jiag398-B15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/infdis\/jiab266","article-title":"Differences in vaginal microbiota, host transcriptome, and proteins in women with bacterial vaginosis are associated with metronidazole treatment response","volume":"224","author":"Serebrenik","year":"2021","journal-title":"J Infect Dis"},{"issue":"S1","key":"2026081702563628500_jiag398-B16","first-page":"1","article-title":"Effects of symptomatic bacterial vaginosis before and after treatment on genital mucosal immunity in women in Bronx, New York and Thika, Kenya.","volume":"32","author":"Keller","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026081702563628500_jiag398-B17","doi-asserted-by":"crossref","first-page":"e16475","DOI":"10.1371\/journal.pone.0016475","article-title":"A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel","volume":"6","author":"Keller","year":"2011","journal-title":"PLoS One"},{"key":"2026081702563628500_jiag398-B18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/jac\/dks151","article-title":"Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring","volume":"67","author":"Keller","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026081702563628500_jiag398-B19","doi-asserted-by":"crossref","first-page":"e8781","DOI":"10.1371\/journal.pone.0008781","article-title":"Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials","volume":"5","author":"Keller","year":"2010","journal-title":"PLoS One"},{"key":"2026081702563628500_jiag398-B20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/498533","article-title":"PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial","volume":"193","author":"Keller","year":"2006","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B21","doi-asserted-by":"crossref","first-page":"e40415","DOI":"10.1371\/journal.pone.0040415","article-title":"Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents","volume":"7","author":"Madan","year":"2012","journal-title":"PLoS One"},{"key":"2026081702563628500_jiag398-B22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/aid.2015.0264","article-title":"Comparison of follicular and luteal phase mucosal markers of HIV susceptibility in healthy women","volume":"32","author":"Thurman","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026081702563628500_jiag398-B23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/aid.2016.0320","article-title":"Comparison of mucosal markers of human immunodeficiency virus susceptibility in healthy premenopausal versus postmenopausal women","volume":"33","author":"Thurman","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026081702563628500_jiag398-B24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1099\/0022-1317-2-3-357","article-title":"Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells","volume":"2","author":"Ejercito","year":"1968","journal-title":"J Gen Virol"},{"key":"2026081702563628500_jiag398-B25","doi-asserted-by":"crossref","first-page":"e88529","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 \u0394gD elicits Fc\u03b3R-effector antibodies that protect against clinical isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"2026081702563628500_jiag398-B26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/jit581","article-title":"Evidence for innate immune system activation in HIV type 1\u2013infected elite controllers","volume":"209","author":"Krishnan","year":"2014","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B27","doi-asserted-by":"crossref","first-page":"e161968","DOI":"10.1172\/JCI161968","article-title":"A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice","volume":"133","author":"Kuraoka","year":"2023","journal-title":"J Clin Invest"},{"key":"2026081702563628500_jiag398-B28","doi-asserted-by":"crossref","first-page":"107648","DOI":"10.1016\/j.isci.2023.107648","article-title":"Antibody attributes, Fc receptor expression, gestation and maternal SARS-CoV-2 infection modulate HSV IgG placental transfer","volume":"26","author":"Mahant","year":"2023","journal-title":"iScience"},{"key":"2026081702563628500_jiag398-B29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/infdis\/jiac284","article-title":"Failure of herpes simplex virus glycoprotein D antibodies to elicit antibody-dependent cell-mediated cytotoxicity: implications for future vaccines","volume":"226","author":"Mahant","year":"2022","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1073\/pnas.1418812112","article-title":"Structure of Fc\u03b3RI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding","volume":"112","author":"Lu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026081702563628500_jiag398-B31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1086\/429622","article-title":"Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization","volume":"40","author":"Cherpes","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026081702563628500_jiag398-B32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1086\/375819","article-title":"Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis","volume":"37","author":"Cherpes","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026081702563628500_jiag398-B33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/09564624231201189","article-title":"Incidence of herpes simplex virus type 2 positivity among women living with human immunodeficiency virus in South Africa","volume":"35","author":"Asare","year":"2024","journal-title":"Int J STD AIDS"},{"key":"2026081702563628500_jiag398-B34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ph3010146","article-title":"Impact of glycosylation on effector functions of therapeutic IgG","volume":"3","author":"Abes","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081702563628500_jiag398-B35","first-page":"388","article-title":"Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV types 1 and 2","volume":"10","author":"Mbopi-Keou","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"2026081702563628500_jiag398-B36","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/JVI.02509-10","article-title":"The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo","volume":"85","author":"Lubinski","year":"2011","journal-title":"J Virol"},{"key":"2026081702563628500_jiag398-B37","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"2026081702563628500_jiag398-B38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","article-title":"Iga Fc receptors","volume":"21","author":"Monteiro","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"2026081702563628500_jiag398-B39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2026081702563628500_jiag398-B40","doi-asserted-by":"crossref","first-page":"e142088","DOI":"10.1172\/JCI142088","article-title":"B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin","volume":"131","author":"Ford","year":"2021","journal-title":"J Clin Invest"},{"key":"2026081702563628500_jiag398-B41","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1086\/314505","article-title":"Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis","volume":"178","author":"Cauci","year":"1998","journal-title":"J Infect Dis"},{"key":"2026081702563628500_jiag398-B42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/mi.2013.120","article-title":"Igg in cervicovaginal mucus traps HSV and prevents vaginal herpes infections","volume":"7","author":"Wang","year":"2014","journal-title":"Mucosal Immunol"},{"key":"2026081702563628500_jiag398-B43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41577-019-0261-1","article-title":"Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2026081702563628500_jiag398-B44","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3389\/fimmu.2019.02110","article-title":"The roles of host and viral antibody Fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity","volume":"10","author":"Jenks","year":"2019","journal-title":"Front Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag398\/70416486\/jiag398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag398\/70416486\/jiag398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:56:48Z","timestamp":1786949808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag398\/8748570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag398","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"jiag398"}}